BACKGROUND: Cell-free RNA in amniotic fluid supernatant reflects developmental changes in gene expression in the living fetus, which includes genes that are specific to the central nervous system. Although it has been previously shown that central nervous systemespecific transcripts are present in amniotic fluid supernatant, it is not known whether changes in the amniotic fluid supernatant transcriptome reflect the specific pathophysiologic condition of fetal central nervous system disorders. In myelomeningocele, there is open communication between the central nervous system and amniotic fluid. OBJECTIVES: The purpose of this study was to identify molecular pathophysiologic changes and novel disease mechanisms that are specific to myelomeningocele by the analysis of amniotic fluid supernatant cell-free RNA in fetuses with open myelomeningocele. STUDY DESIGN: Amniotic fluid supernatant was collected from 10 pregnant women at the time of the open myelomeningocele repair in the second trimester (24.5AE1.0 weeks); 10 archived amniotic fluid supernatant from sex and gestational ageematched euploid fetuses without myelomeningocele were used as controls (20.9AE0.9 weeks). Differentially regulated gene expression patterns were analyzed with the use of human genome expression arrays.
I
n the United States, 1500 infants are born annually with myelomeningocele. 1 A relatively recent therapeutic breakthrough for the condition was the development of fetal surgery that can improve motor function and reduce the risk of the development of hydrocephalus in affected infants. 2 Although the long-term outcomes for children who underwent fetal surgery have yet to be determined, some children are still expected to have significant motor and cognitive impairments, based on a cohort study that was implemented before a randomized trial. 3 Additionally, not all fetuses are candidates for fetal surgery, and there are considerable maternal and fetal risks. 3, 4 Alternative and/or complementary medical approaches to treatment are warranted.
To develop medical treatments, the fetal molecular pathophysiologic condition of myelomeningocele must be investigated rigorously. This has not yet been done, partly because of its complexity and heterogeneity. 5 The understanding of pathologic mechanisms in the fetus has been limited by a lack of tools to evaluate its dynamic molecular interactions in living human fetuses. Transcriptomic analysis of cell-free RNA (cfRNA) in amniotic fluid (AF) reflects fetal development in real time. Gene expression can be assessed from various organs that include brain and spinal cord. [6] [7] [8] [9] Previous reports of the AF cfRNA transcriptome analysis with the use of microarrays identified specific and molecular mechanisms in fetal diseases such as aneuploidies, 10, 11 twintwin transfusion syndrome, 12 maternal obesity, 9 and fragile X syndrome. 13 We hypothesized that analysis of the AF transcriptome using cfRNA will provide novel insights into myelomeningocele pathophysiologic condition that will lead to the identification of novel therapeutic targets. We also hypothesized that myelomeningocele AF transcriptome analysis will provide more transcripts that originate from the central nervous system (CNS) than healthy fetuses or other conditions, because fetal CNS tissue is exposed directly to the AF. Myelomeningocele has heterogeneous genetic and environmental pathophysiologies. 5, 14, 15 A systems biology approach may be ideal to analyze the disease to identify common molecular pathways that are relevant to disease mechanisms. In this study, we aimed to determine specific molecular pathways and genes that are differentially expressed in fetuses with myelomeningocele. We also tested whether genes from the CNS are overrepresented in AF from fetuses with 
Methods

Study design
This study compared AF cfRNA transcription between second-trimester fetuses with myelomeningocele and sex-and relatively gestational agematched control fetuses. Although case samples (myelomeningocele) were collected prospectively, the control samples were from previous studies that were performed in our laboratory. 8, 9 The study was approved by the Institutional Review Boards of Tufts Medical Center (#8908) and Children's Hospital for Philadelphia (#14-010958).
Subjects and samples
Ten pregnant women who underwent fetal surgery between 22 and 27 weeks of gestation for myelomeningocele at Children's Hospital for Philadelphia were enrolled into the study prospectively between December 2014 and September 2015. All subjects met the criteria of the previous randomized controlled study for myelomeningocele repair. 2 The control AF samples consisted of residual discarded second-trimester clinical samples from the Cytogenetics Laboratory at Tufts Medical Center that originally were obtained and analyzed for previous studies from June 2011 to April 2012. 8, 9, 16 RNA was extracted within 6 months after collection. These samples were collected from pregnant women carrying structurally normal fetuses who underwent diagnostic amniocenteses for standard indications (advanced maternal age, abnormal serum screening test). The control fetuses were confirmed to have normal karyotypes with cytogenetic tests. Archived samples were used because of the nationwide decrease in the frequency of diagnostic amniocentesis after the introduction of noninvasive prenatal testing. The gestational age of the control fetuses could not be matched precisely because most of the diagnostic amniocenteses occur at <22 weeks, and fetal surgery occurs at 23e26 weeks.
Under general anesthesia, pregnant women underwent open fetal surgery, as previously described. 2 After the uterus was exposed and incised, 5e10 mL of AF, which would otherwise have been discarded, were aspirated through intact amniotic membranes with a blunt plastic cannula that was attached to a 20-mL syringe. On completion of the surgery, the lost AF volume was replaced with warmed normal saline solution by standardized surgical techniques. AF samples were frozen immediately at e20 C to be sent to Tufts Medical Center, where the rest of the analyses were performed. On arrival at Tufts Medical Center, the samples were stored in a e80 C freezer until RNA extraction.
All control samples were processed for RNA extraction within 6 months after sample collection between December 2011 and June 2012 with the use of the same method as in our previous study. 16 Among 10 controls, 5 were processed on microarrays within 6 months after collection. The extracted RNA from the other 5 samples were stored in a e80 C freezer until hybridization on microarrays in June 2015. Microarray quality was not different between the 5 freshly processed samples and the 5 samples that were processed later (t-tests of the scale factors and percentage present calls between the 2 groups have probability values of .25 and .28, respectively).
RNA extraction
Within 6 months after collection, the AF samples from the fetuses with myelomeningocele were thawed and centrifuged at 300g at 4 C for 10 minutes and separated into AF supernatant (AFS) and pellet. Control samples were centrifuged with the same method but right after the collection at the Cytogenetics Laboratory. RNA was extracted from AFS with Qiagen Isolation of Circulating Cell-Free Nucleic Acids and the Qiagen RNeasy MinElute (Qiagen, Venlo, The Netherlands) cleanup step, as previously described. 16 Transcriptome microarray and quality control
Extracted RNA was amplified with the use of the Ovation Pico WTA System V2 (NuGEN, San Carlos, CA). The quantity and purity of amplified complementary DNA (cDNA) was measured with the use of Nanodrop (Thermo Scientific, Wilmington, MA) at the single-stranded DNA setting to assure a sufficient amount of cDNA and quality. The amplified cDNA was fragmented and biotin-labeled with the FL-Ovation cDNA Biotin Module V2 (NuGEN), according to the manufacturer's instructions. Biotin-labeled and fragmented cDNAs were hybridized to the AffymetrixGeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA), as previously described. 6 We chose gene expression microarrays over RNA sequencing for 2 reasons. Previous studies in our laboratory showed that microarrays detected a greater number of genes than RNA sequencing from the same sample. 17 Also, microarray data can be used directly to test hypotheses regarding novel therapies with the use of the connectivity map. 18 After quality control assessment with Affymetrix software (version 5.0; Affymetrix), the raw microarray data were normalized with the use of the affyPLM package in Bioconductor (http://www. bioconductor.org) in R (version 3.2.5; R Foundation for Statistical Computing, Vienna, Austria) for further analysis. 19 The normalization was performed with the 3-step function with the use of ideal mismatch as the background correction technique, quantile normalization, and summarization with the Tukey-Biweight algorithm. Microarray data were deposited in Gene Expression Omnibus (accession number GSE101141). Differentially regulated genes between fetuses with myelomeningocele and controls were identified with the use of paired ttests with the Benjamini-Hochberg adjustment (adjusted probability value, <.05) to control the false discovery rate, despite multiple tests. 20, 21 We previously demonstrated that the use of paired t-tests (provided the pairings are fixed before the analysis and based solely on clinical characteristics) can allow us to see phenotypic differences, despite the variability introduced by gestational age.
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Identification of differentially regulated genes, their functional annotations, and functional pathway analysis
Genes that were significantly up-or down-regulated as defined earlier in this article and that showed consistent up-or down-regulation in the indicated direction in at least 8 of the 10 pairs were identified as "common" differentially regulated genes in myelomeningocele. We chose to use this additional directional filter to identify truly common pathways that are relevant to myelomeningocele and to avoid false conclusions based on outliers. These genes were uploaded to the Ingenuity Pathway Analysis tool (IPA; version 28820210; Ingenuity Systems, Redwood City, CA) to determine functional annotations of differentially expressed genes and specific genetic pathways that were significantly different between the case and control AFS samples. Based on a manually curated gene data base (mostly adult and some fetal) of functional annotations and biologic interactions, IPA identifies molecular pathways and predicts downstream effects on biologic and disease processes. 23 Analyses identified differentially regulated pathways that were reported with false-discovery rates and bias-corrected Z-scores, where calculated. Z-scores provided both magnitudes and directions of differential regulation (ie, how much the pathways were activated or inhibited). 23 The functional annotation of individual genes was also investigated manually with the use of available online databases such as PubMed.
Tissue specificity analysis
BioGPS is a gene expression annotation portal and data resource that includes gene "atlases" that measure genomewide expression in a range of tissues and platforms. 24 To identify tissuespecific transcripts, we downloaded the human gene expression atlas from Bio-GPS in which samples were profiled with the use of Affymetrix U133A arrays. 24 We computed the median expression level of each gene across all nonmalignant samples. We then defined tissue-specific genes as those in which maximum expression in a particular tissue type was at least 30 multiples of the median and whose next highest tissue type had expression levels no more than one-third as high as the maximum for that gene.
To determine whether AFS of myelomeningocele contains more CNS transcripts than that of controls, we identified CNS-specific probes, meaning probes that were specific to CNS-derived tissues in BioGPS as described earlier, in each "core transcriptome," the set of probes called "present" in at least 8 of 10 samples in either the cases or the controls. Using the Fisher's exact test, we determined whether the probability of the presence of CNSspecific probes in the core transcriptome is different for the myelomeningocele samples and the controls. 6 
Results
Clinical characteristics of subjects
The clinical characteristics of study subjects are listed in Table 1 . The gestational age of fetuses could not be matched in absolute because the majority of diagnostic amniocenteses occur at <22 weeks in control fetuses (meanAEstandard deviation, 20 We have performed batch analysis in Combat to test whether batch effects that reflected these differences influenced our results. 25 There did appear to be some batch differences between most of the immediately processed controls and most of the controls that were hybridized later, but there were outliers in each group that raised questions about the possible cause of this effect, given the small numbers of samples in each group.
Combat normalization mitigated, but did not eliminate, this effect because we observed that all 284 differentially regulated genes were still among the top differentially expressed genes after Combat normalization. We have also run a differential expression analysis that compared the control samples that were processed within 6 months to those processed after 3 years. None of the 284 genes that we have identified as differentially expressed in myelomeningocele were seen to be regulated differentially between control batches. Therefore, we do not believe that this unavoidable technical factor meaningfully influenced our results.
Functional annotations of genes differentially expressed in fetuses with myelomeningocele
Differential gene expression analysis between cases and controls was carried out in R. Gene annotation of probe sets is based on the IPA database. Table 2 lists the top 10 most up-and down-regulated genes in myelomeningocele cases vs controls. Eight of these 20 genes had known roles in spinal cord and neuronal development, but not in association with myelomeningocele (GFAP, GAP43, ZEB1, C1orf6, ACAP1, SKI, SEMA5A, TSHZ3). The most dramatically upregulated gene (172-fold) was SERPINB6.
Among the entire list of differentially expressed genes that were identified by IPA, 20 genes with significant roles in brain and spinal cord development were identified. The genes involved planar cell polarity, spinal cord ventral-dorsal axis development, neuronal differentiation, axonal development, Schwann cell development, motor neuron survival, synapse formation, and neuronal injury and repair (Table 3 ). In the same list, 33 genes that were associated with inflammation and neurodegeneration were identified (Table 4) . These genes involve migration of inflammatory cells, accumulation of neutrophils, neuroinflammation, and neurologic injury.
Functional pathway analysis
IPA identified 24 pathways that were associated significantly with and Wnt signaling pathways (glioblastoma multiforme signaling; Z-score, e1.34) were down-regulated (Table 5 ; Supplementary Figure) .
Tissue-specific expression of genes
Among 284 differentially regulated genes, tissue specificity analysis identified 28 genes (10%) that were highly specific in tissue origin. Among them, 12 genes (42%) were specifically expressed in the CNS, brain, and spinal cord (Table 6) . GFAP, C1orf61, FEZ1, and SCRN1 are known to be expressed in the spinal cord. GAP43, TCEAL2, TUBB2B, FABP7, C1orf61, and DOK5 are known to be expressed in the fetal brain (FABP7 and DOK5 are solely expressed in fetal brain). These genes encode diverse categories of proteins, which carry diverse functions in CNS, such as neuronal migration (TUBB2B, FABP7), neuronal differentiation (GFAP, C1orf61, MTUS1), 26 neuronal resilience to various stresses (GFAP, MT3), 27 axon development (GAP43, FEZ1), synaptic transmission, and intercellular signaling in neurons (SYNJ1, MTUS1, SCRN1; Table 6 ). 28 Of 595 CNS-specific probes on the Affymetrix U133A arrays, the myelomeningocele "core transcriptome" expressed more CNS-specific probes than the "core transcriptome" of the controls (135 vs 84 probes; P¼.00017, Fisher's exact test).
Comment
In this study, human gene expression analysis of living fetuses with AFS RNA identified novel and known genes that are involved in the molecular pathophysiologic condition of myelomeningocele, such as pathways that are associated with spinal cord and neuronal development and robust inflammation. In particular, the extent of inflammation in the affected fetuses is a novel observation. The tissue specificity analysis identified CNSspecific genes. Our overall findings suggest that a systems biology approach through analysis of the AF cfRNA transcriptome could provide insights into the fetal molecular pathophysiologic condition of myelomeningocele, along with the Example of differentially expressed genes in fetuses with myelomeningocele with significant roles in inflammation and neurodegeneration a
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Dysregulation of spinal and neuronal developmental genes and pathways in the second-trimester fetuses with myelomeningocele
It is notable that the original annotations in IPA were made based on adult tissue. In contrast, the functional annotations in this study were interpreted here in the context of embryonic and fetal physiologic condition. This showed that various spinal and neuronal development genes and pathways were differentially regulated in fetuses with myelomeningocele. Among the 3 significantly altered pathways, those denoted as "glioblastoma multiforme signaling" and "neuropathic pain signaling in dorsal horn" in adult tissue also represent embryonic and fetal Wnt signaling pathways (Table 3) . One of the Wnt signaling subpathways, planar cell polarity pathway, induces the earliest steps in neurulation "conversion extension" (lengthening and narrowing of the initially disc-shaped neural plate), the failure of which is speculated to cause neural tube defects. 5 In this study, the fetuses with myelomeningocele had significantly down-regulated pathways and associated genes (Wnt5A, PRICKLE2).
Surprisingly, this study also identified novel genes and pathways differentially regulated in fetuses with myelomeningocele that involve multiple distinct steps of spinal and neural development beyond neurulation processes, such as spinal cord ventral-dorsal axis development (Wnt1, Wnt5A, SKI, GPR37 29, 30 ), neuronal differentiation, axonal development (Wnt5A, ITPR1, PLCB3, PLCE1, ACAP1, SEMA5A, and DRAXIN 29, 30 ), dorsal root ganglion development (SEMA5A, NEUROD, and ZEB1
31
), Schwann cell development, motor neuron survival, synapse formation, and neuronal injury and repair (Table 3) . Disturbances in formation of the corticospinal tract may explain how progressive motor impairment occurs in myelomeningocele. 32 Certain genes that have no known association with spinal or neural development were also significantly upregulated, such as SERPINB6. In humans, SERPINB6 mutations are associated with sensorineural hearing loss. 33 In human fetuses at 21 weeks of gestation, SERPINB6 is expressed diffusely in the developing brain (www. brainspan.org database; no information available for spinal cord), but its function in fetal development is unknown. SERPINB6 is also known as proteinase inhibitor 6 or placental thrombin inhibitor and may contribute to the secondary disease of myelomeningocele for its role in antiviral and antiapoptotic effects and fibrinolysis.
34-36 SERPINB6 also endogenously inhibits neuropsin, which modifies synaptic plasticity and long-term potentiation. 37, 38 Many other genes with previously unknown associations with myelomeningocele or spinal development were up-or downregulated, but none to the extent of SERPINB6 (Table 2) .
Although some of these pathways identified function in an early embryonic phase, such as neurulation, some function in later gestation when axonal development and synapse formation are active. Considering such broad temporal distribution, cfRNA in AF may have the nature of a real-time identification of currently functioning genes and pathways, as well as being a potential "time capsule" of accumulated information of formerly expressed genes in living fetuses. 7 Further investigation is needed to test this hypothesis.
Inflammation and neurodegeneration as the critical fetal neuropathologic condition of myelomeningocele
Among all analyses in this study for either pathways (Table 5) or individual molecular analyses (Table 4) , inflammation and neurologic injury stand out consistently as the most prominent transcriptomic alterations in fetuses with myelomeningocele. There were differential regulations in neuroinflammation (GFAP, SREBF2 and AQP4), microglia activation (ERBB3 and HMGB1 via receptor of advanced glycation endproducts cascade), axonal regeneration (GAP43), 39, 40 and synaptogenesis (ITPR1 41 ). GFAP, the second most upregulated gene (80-fold) in this study is an intermediate filament protein and a marker of mature/reactive astroglia, which is one of the primary responders to neural injuries. GFAP is known to increase in the AF of a retinoic acide induced rat myelomeningocele model, potentially reflecting severity of the spinal defect and neurologic impairments. 42 Not only the injury process, but also the regenerative responses, may be activated in fetuses with myelomeningocele, such as axonal regeneration (GAP43) 39, 40 and synaptogenesis (ITPR1). 41 Former studies also reported abnormal neuronal development, inflammation, and gliosis in placode tissue of fetuses with myelomeningocele by immunohistologic condition in foetopsy specimens 43 and surgically excised tissues. 44 Neuroinflammation, injuries, and regeneration may constitute secondary diseases in fetuses with 
Transcripts specific to CNS
Here we sought less invasive ways to identify tissue origins of differentially regulated genes in AF without collecting fetal tissue. Our analysis showed that a high portion (40%) of the tissue-specific transcripts were specific to the CNS. Most of them were not expressed in the spinal cord, although this might be a biased view, because less in situ expression data are available for the fetal spinal cord than brain in the BioGPS database.
Genes that are expressed highly specifically in the CNS have relevant developmental functions in the second trimester, such as neuronal differentiation, migration, axonal development, and maintenance of neurons (Table 6 ). These genes originated broadly from various CNS tissues and include cerebrum and cerebellum beyond the local spinal cord malformation (Table 6 ). Such broad distribution of differentially regulated genes may explain cognitive impairments that are observed in adults with myelomeningocele that cannot be explained by the primary spinal lesion or complications of hydrocephalus. 45 Analysis of the core transcriptomes showed that AFS of fetuses with myelomeningocele contains more transcripts that are specific to CNS compared with that of controls. It is not known whether CNS transcripts in AFS may have originated at a time when neural tube was open or whether they are expressed actively in the secondtrimester fetus. In the case of myelomeningocele, there is another possibility that CNS transcripts may continue to "leak out" with cerebrospinal fluid. Further study is needed to answer these questions.
Study limitations
One limitation of transcriptomic analysis that used cfRNA in AFS is the fact ajog.org
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that the tissue origins of the cell-free RNAs cannot be traced, resulting in a lack of in situ information. 7 Although our tissue specificity analysis may have demonstrated neuronal tissue origin of these altered genes, further in situ analysis is warranted. It is encouraging that former studies have shown similar pathologic processes (expression of glial fibrillary acidic protein and proinflammatory molecules) in excised fetal placode tissues. 43, 44 In future efforts, excised fetal placode tissues can be an ideal model to test our hypotheses derived from this study. Transcriptomic analysis of AFS samples has an advantage over tissue analysis because it can be applied to fetuses with myelomeningocele that are not candidates for fetal surgery.
Our study is also limited by the fact that we could not match gestational ages completely between groups because of inevitable differences in the timing of amniocentesis between control (diagnostic) and case (surgical) groups. This may contribute to some of the changes that were observed in this study, which may be caused by different developmental stages. However, for practical and ethical reasons, relative matching was considered to be the most reasonable alternative.
In summary, our study has shown dysregulation of multiple distinct steps in spinal and neural development and systemic activation of neuroinflammation, neurodegeneration, and neuronal repair in presurgical fetuses with myelomeningocele, which may contribute to progressive impairment of motor and cognitive functions during the pregnancy. The study has also shown that fetuses with myelomeningocele have a greater number of CNS-specific transcripts in the AFS compared with controls. This study provides proof of principle that a systems biology approach with the use of the AFS cfRNA transcriptome identifies common molecular pathophysiologic condition in living fetuses with myelomeningocele. The list of differentially regulated genes and pathways from this study will also be used to identify potential drug targets. For example, by using the connectivity map (portals.broadinstitute.org/cmap/), 18 we plan to identify compounds that could reverse the gene signature that is associated with myelomeningocele. Insights from this study therefore may lead to identification of potential targets for fetal treatment in combination with fetal surgery. n
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Network
Network associated with differentially regulated pathways in the second-trimester fetuses with myelomeningocele as generated by Ingenuity Pathways Analysis (version 28820210; Ingenuity Systems, Redwood City, CA). A, Leukocyte extravasation; B, glioblastoma multiforme; C, neuropathic pain. Differentially regulated genes are shaded. Original Research OBSTETRICS ajog.org
